Clinical trials: COVID-19 Mortality
Covid19
Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
- Trial name
- DAMPENCOVID (NCT04445285)
- Testing
- Pulmozyme/ Recombinant human deoxyribonuclease (rh-DNase), 0.9%sodium chloride
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Jon Simmons
Covid19, Liver Diseases
Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes
Of patients admitted to an internal medicine ward with internistic diagnosis/es together with COVID-19, substantial proportion has elevated liver enzymes.
- Trial name
- SILCOVINT-21 (NCT04816682)
- Testing
- Silymarin
- Where
- 2 sites in Slovakia
- Volunteers
- 30 people
- Sponsor
- F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica
SARS-CoV 2, COVID
In-vitro Diagnostic Test to Predict COVID-19 Mortality and Disease Severity
The COVID-19 Androgen Sensitivity Test is a non-invasive In-Vitro Diagnostic device that utilizes Next Generation Sequencing Technology (NGS).
- Conditions
- SARS-CoV 2, COVID, COVID-19, Androgenetic Alopecia
- Trial name
- NCT04368897
- Testing
- CAG length <22, CAG length >=22
- Where
- Spain
- Sponsor
- Applied Biology, Inc.
Acute Kidney Injury
Mortality and Morbidity Associated With New Onset Acute Kidney Injury in Critically Ill COVID-19 Infection Patients
This study explored the incidence of morbidity and mortality associated with AKI in critically ill adult patients infected with COVID-19. There are two groups for comparison. Group1.
- Trial name
- NCT05964088
- Where
- United States
- Volunteers
- 267 people
- Sponsor
- Arrowhead Regional Medical Center
Sars-CoV2, Covid-19
Effectiveness and Safety of Convalescent Plasma in Patients With High-risk COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected the global population with significant morbidity and mortality.
- Trial name
- NCT04425837
- Testing
- SARS-CoV-2 convalescent plasma treatment, Standard care
- Where
- Colombia
- Volunteers
- 236 people
- Sponsor
- Fundación Santa Fe de Bogota
Covid19, Ultrasound
Lung Ultrasound in COVID-19 Patients
To assess the prognostic performance of an early global LUS score with respect to the mortality in ICU and duration of ventilation.
- Conditions
- Covid19, Ultrasound, ARDS
- Trial name
- LUS-COVID (NCT04487769)
- Where
- Netherlands
- Volunteers
- 137 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Diabetes Mellitus, Covid19
Clinical Phenotype and Outcomes of Inpatients With COVID-19 and Diabetes
Patients with diabetes have been listed as people at higher risk for severe illness from COVID-19. Moreover, the relationship between diabetes-related phenotypes and the severity of COVID-19 remains unknown.
- Trial name
- NCT04550403
- Where
- Italy
- Volunteers
- 757 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
COVID-19 Pandemic, Vitamin D Deficiency
COVID-19 and Vitamin D: Length of Hospital Stay and Mortality
The lack of a pharmacological treatment in the COVID-19 pandemic has pushed scientists to search for this issue. Maintaining optimal health is parallel to adequate and balanced nutrition.
- Trial name
- NCT05221983
- Where
- Turkey (Türkiye)
- Volunteers
- 168 people
- Sponsor
- Yuksek Ihtisas University
COVID-19 Confirmed Cases, COVID-19 Mortality
COVID - AirPollution
Epidemiological data have related particulate matter (PM), nitrogen dioxide (NO2) and ozone (O3) to COVID-19 morbidity and mortality at the population level.
- Trial name
- NCT04463862
- Where
- 8 sites in Belgium, France
- Volunteers
- 660 people
- Sponsor
- University Hospital, Strasbourg, France
Mortality, Intensive Care Unit
Effect of Favipiravir on Mortality in Patients With COVID-19 at a Tertiary Center Intensive Care Unit
Effect of Favipiravir and Lopinavir-Ritonavir on Mortality in a Tertiary Center Intensive Care Unit: Single Center Experience
- Trial name
- NCT04645433
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Sisli Hamidiye Etfal Training and Research Hospital
Covid19, Respiratory Tract Infections
Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration
Project is designed as a comprehensive population-based epidemiological study in Upper-Silesian Conurbation (Poland) aiming at: 1. analysis of available data on incidence and mortality due to COVID-19 and 2.
- Conditions
- Covid19, Respiratory Tract Infections, Severe Acute Respiratory Syndrome, Corona Virus Infection
- Trial name
- EpiSARS2 (NCT04627623)
- Testing
- IgM and IgG antibodies assay
- Where
- Poland
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- Medical University of Silesia
COVID-19 Pandemic
External Validation of the 4C Mortality Score for Hospitalised Patients With COVID-19 in a Tunisian Cohort
Risk prediction scores are important tools to support clinical decision-making for patients with coronavirus disease (COVID-19).
- Trial name
- 4C (NCT05498324)
- Where
- Tunisia
- Volunteers
- 1,500 people
- Sponsor
- University of Monastir
COVID-19, SARS-CoV-2
Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era
This retrospective real-world target trial emulation uses complete Czech nationwide registry data to evaluate whether molnupiravir treatment is associated with lower COVID-19 mortality during the Omicron era.
- Trial name
- MOLCOVred (NCT07720596)
- Testing
- Molnupiravir
- Where
- Czechia
- Volunteers
- 1,795,570 people
- Sponsor
- Charles University, Czech Republic
COVID-19
The LUSZ COVID-19 Severity Index: A Prognostic and Predictive Score of Mortality for Hospitalized Patients With Covid-19
The coronavirus disease 2019 (COVID-19) has spread rapidly and caused a global pandemic, as defined by the WHO, within a short period of time.
- Trial name
- LUSZ_SCORE (NCT05848427)
- Testing
- LUSZ P
- Where
- 2 sites in Lebanon
- Volunteers
- 1,000 people
- Sponsor
- Lebanese University
COVID19
Optimising Resource Allocation Via Prediction of Outcomes for Covid-19
The investigators plan to use all of the information available within their local NHS hospitals Trust to work out what happens to people admitted with both suspected and proven Covid-19 infections.
- Trial name
- NCT04473105
- Where
- United Kingdom
- Volunteers
- 11,134 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Tocilizumab, COVID-19
Effect of Tocilizumab on Intensive Care Patients With COVID-19 Pneumonia, a Retrospective Cohort Study
Although its safety and efficacy in the COVID-19 patient population are still unclear, tocilizumab is one of treatment. Tocilizumab is a U.S.
- Conditions
- Tocilizumab, COVID-19, Critical Care, Mortality
- Trial name
- NCT04893031
- Testing
- Tocilizumab
- Where
- Turkey (Türkiye)
- Volunteers
- 213 people
- Sponsor
- Karadeniz Technical University
Covid19
SOLIDARITY Finland Long-COVID (Remdesivir Long-term Follow-up Study of COVID Patients)
SOLIDARITY Finland Long-COVID trial assesses the effects of remdesivir + standard of care (SoC) vs. only SoC on long-COVID symptoms and quality of life (QoL) using questionnaires at one and two years post-discharge.
- Trial name
- NCT04978259
- Testing
- Remdesivir
- Where
- Finland
- Volunteers
- 202 people
- Sponsor
- Clinical Urology and Epidemiology Working Group
COVID-19, Cytomegalovirus (CMV), Tocilizumab, Anakinra, Mortality
The Relationship Between CMV* Reactivation and Anti-cytokine Treatment in Critical COVID-19 Patients
The risk of secondary infection is high in critical patients hospitalized with the diagnosis of COVID-19. Immunosuppressive treatments are commonly used in critical COVID-19 patients, and immune dysfunction and CMV reactivation…
- Trial name
- Cytomegalovir (NCT05419206)
- Testing
- CMV DNA analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 167 people
- Sponsor
- Ramazan Gozukucuk
COVID-19
A Single-center Retrospective Study to Find Prediction Factors Related to Mortality of COVID-19 Patients.
In the single-centered, retrospective study, 306 hospital patients (including 129 diabetes and 177 non-diabetes patients) confirmed with SARS-CoV-2 infection were enrolled in Tongji Hospital, Wuhan, China.
- Trial name
- NCT04365634
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Tongji Hospital
COVID-19, Coronavirus Infection
Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"
The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients…
- Conditions
- COVID-19, Coronavirus Infection, Virus Disease, Acute Respiratory Infection
- Trial name
- NCT04403100
- Testing
- Hydroxychloroquine Sulfate Tablets, Lopinavir/ Ritonavir Oral Tablet, Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets
- Where
- 4 sites in Brazil
- Volunteers
- 1,968 people
- Sponsor
- Cardresearch